Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $25.00 at Maxim Group

Zevra Therapeutics (NASDAQ:ZVRA) had its target price boosted by Maxim Group from $18.00 to $25.00 in a research report released on Tuesday morning, MarketBeat Ratings reports. Maxim Group currently has a buy rating on the stock.

Several other brokerages have also issued reports on ZVRA. Canaccord Genuity Group cut their price target on Zevra Therapeutics from $24.00 to $22.00 and set a buy rating on the stock in a research note on Wednesday, September 18th. Cantor Fitzgerald restated an overweight rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. HC Wainwright raised their target price on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the company a buy rating in a research note on Friday, September 20th. Finally, William Blair raised shares of Zevra Therapeutics to a strong-buy rating in a research note on Friday, August 30th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of Buy and an average price target of $21.00.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $6.92 on Tuesday. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $8.95. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The firm’s 50 day moving average is $7.16 and its 200-day moving average is $5.76. The firm has a market capitalization of $364.13 million, a price-to-earnings ratio of -5.13 and a beta of 1.94.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period in the prior year, the company posted ($0.15) EPS. Sell-side analysts forecast that Zevra Therapeutics will post -1.59 EPS for the current fiscal year.

Insider Activity

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, July 12th. The stock was acquired at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the transaction, the director now owns 30,000 shares of the company’s stock, valued at $176,100. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 22,000 shares of company stock valued at $140,340 in the last quarter. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors have recently added to or reduced their stakes in ZVRA. Price T Rowe Associates Inc. MD acquired a new stake in Zevra Therapeutics in the 1st quarter valued at approximately $64,000. The Manufacturers Life Insurance Company grew its stake in shares of Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares in the last quarter. Focus Financial Network Inc. ADV bought a new position in shares of Zevra Therapeutics during the 4th quarter worth approximately $141,000. Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $177,000. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Zevra Therapeutics by 102.4% in the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after purchasing an additional 17,557 shares in the last quarter. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.